Jobs at OpenEvidence

Recomputed daily from public data: capital freshness (0-35) + hiring velocity (0-30) + pay transparency (0-20) + employer rating (0-15; unrated scores the neutral 7), minus up to 10 for documented headwinds (lawsuits, layoffs, leadership churn). Transparent formula, not investment or career advice.

700Mtotal raised

Series D, $250M, 2026last round

Latestage

MiamiHQ

2022founded

~119headcount (as of 2026-05)

Founders: Daniel Nadler (founded Kensho (sold to S&P Global for ~$550M, 2018); Harvard PhD) · Zachary Ziegler (co-founder & CTO, Harvard ML researcher)

Backed by: Sequoia, GV, Kleiner Perkins, Thrive Capital, Coatue, Blackstone

Signals

Fresh capital (raised in the last 12 months)

$250M Series D at a $12B valuation (Jan 2026) co-led by Thrive and DST; valuation doubled in about three months.

In the news

(MSK) and OpenEvidence Partner to Advance Precision Oncology at the Point of Care | Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center · 2026-09-16

New Penn Med AI tool aims to improve clinical decision-making The Daily Pennsylvanian · 2026-09-16

A Premier Cancer Hospital Makes Its Data Available To Doctors Nationwide Through OpenEvidence Forbes · 2026-09-16

OpenEvidence deepens oncology push to build specialized AI agents, launches new AI model family Fierce Healthcare · 2026-09-03

Auto-pulled from Google News, refreshed daily; headlines belong to their publishers

Momentum index 51/100 = capital freshness (0-35) + hiring velocity (0-30) + comp transparency (0-20) + workplace rating (0-15), minus documented headwinds. Recomputed daily; not investment or career advice.